[{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.85999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0.75,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.85999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0.85999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.85999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":1.3,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":1.5,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"VAX-24","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":1.5,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":1.5,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VAX-24","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"VAX-24","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"31-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"31-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Sutro Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.16,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Vaxcyte","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Vaxcyte"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Sutro Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0.16,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.16,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Vaxcyte","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Vaxcyte"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.57999999999999996,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.57999999999999996,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0.5,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.57999999999999996,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0.57999999999999996,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.57999999999999996,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ BofA Securities"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Lonza Biologics Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Expanded Collaboration","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Vaxcyte","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Vaxcyte"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"31-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"31-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"31-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"31-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VAX-24","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VAX-31","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Undisclosed","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Undisclosed","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"31-valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaxcyte \/ Inapplicable"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"31-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxcyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Vaxcyte
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
